Core Insights - Eli Lilly (LLY.US) has initiated the first Phase III clinical trial (FRAmework-01) for its FRαADC drug LY4170156, which is developed by Mablink Bioscience, a company acquired by Eli Lilly [1] - LY4170156 utilizes a payload of the topoisomerase I inhibitor irinotecan, with a drug-to-antibody ratio (DAR) of 8 [1] - According to NextPharma database, there are currently 27 FRαADC drugs in development globally, with 11 in clinical stages [1] - Apart from the already marketed drug somatuzumab, LY4170156, Rinatabart sesutecan (Genmab), and BAT8006 (Baiyoutai) are the three fastest progressing drugs, all having initiated Phase III clinical trials [1]